Masafumi Ikeda
#161,182
Most Influential Person Now
Researcher
Masafumi Ikeda's AcademicInfluence.com Rankings
Masafumi Ikedacomputer-science Degrees
Computer Science
#9284
World Rank
#9751
Historical Rank
Computational Linguistics
#2213
World Rank
#2235
Historical Rank
Machine Learning
#4024
World Rank
#4072
Historical Rank
Artificial Intelligence
#4361
World Rank
#4421
Historical Rank
Download Badge
Computer Science
Masafumi Ikeda's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science University of Tokyo
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Masafumi Ikeda Influential?
(Suggest an Edit or Addition)Masafumi Ikeda's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020) (2450)
- Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin (2004) (556)
- Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. (2013) (521)
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan (2014) (515)
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020) (461)
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial (2019) (298)
- A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation (2007) (260)
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma (2016) (255)
- Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. (2021) (228)
- Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features (2002) (204)
- Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update (2014) (189)
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. (2019) (180)
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). (2021) (172)
- Chemotherapy for hepatocellular carcinoma: current status and future perspectives (2018) (162)
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study (2019) (156)
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update (2021) (154)
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (147)
- Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. (2019) (146)
- Phase II study of S-1 in patients with advanced biliary tract cancer (2004) (144)
- Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. (2010) (140)
- Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study (2017) (136)
- Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon (2005) (134)
- Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer (2014) (134)
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). (2018) (123)
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021) (122)
- Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. (2001) (121)
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma (2015) (120)
- An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer (2005) (117)
- Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer (2016) (114)
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients (2016) (109)
- A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements (2020) (109)
- Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial (2016) (102)
- Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer (2004) (100)
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset (2019) (99)
- Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy (2000) (95)
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma (2011) (95)
- Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin (2005) (93)
- Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805) (2013) (90)
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (2022) (86)
- Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. (2021) (83)
- Transcatheter Arterial Chemotherapy with and without Embolization in Patients with Hepatocellular Carcinoma (2004) (83)
- Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). (2020) (81)
- A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (2018) (80)
- Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy (2001) (80)
- Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma (2013) (79)
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer (2011) (78)
- A phase II trial of continuous infusion of 5‐fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma (2005) (77)
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer (2020) (74)
- Analysis of Prognostic Factors Affecting Survival After Initial Recurrence and Treatment Efficacy for Recurrence in Patients Undergoing Potentially Curative Hepatectomy for Hepatocellular Carcinoma (2007) (72)
- Phase I trial of gemcitabine in patients with advanced pancreatic cancer. (2001) (72)
- Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. (2013) (71)
- Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma (2016) (71)
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). (2019) (70)
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer (2008) (69)
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study (2015) (68)
- Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. (2010) (65)
- Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels (2015) (65)
- Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma (2014) (64)
- Phase 1 and pharmacological trial of OPB‐31121, a signal transducer and activator of transcription‐3 inhibitor, in patients with advanced hepatocellular carcinoma (2015) (63)
- A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). (2018) (63)
- A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer (2002) (61)
- A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results (2019) (61)
- Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients (2009) (55)
- A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer (2005) (53)
- A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. (2013) (52)
- New developments in systemic therapy for advanced biliary tract cancer (2018) (51)
- Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. (2009) (51)
- Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients (2010) (50)
- A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. (2020) (50)
- S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. (2017) (49)
- A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer (2013) (49)
- A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). (2020) (49)
- Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial (2012) (48)
- Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment (2011) (47)
- Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics (2013) (47)
- Evaluation of the Therapeutic Effect of Transcatheter Arterial Embolization for Hepatocellular Carcinoma (2000) (46)
- Immunotherapy for hepatocellular carcinoma: current status and future perspectives (2018) (46)
- Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results (2017) (45)
- Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (2020) (45)
- Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. (2008) (44)
- IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. (2018) (44)
- Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification (2018) (42)
- Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON (2016) (40)
- Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma (2018) (40)
- Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. (2014) (40)
- C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer (2016) (40)
- Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future (2015) (39)
- Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study (2018) (39)
- Abdominal Pain in Patients with Resectable Pancreatic Cancer with Reference to Clinicopathologic Findings (2001) (39)
- Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial. (2018) (38)
- Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization (2014) (38)
- Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma (2011) (38)
- A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis (2013) (38)
- Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. (1997) (37)
- Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial (2017) (37)
- Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial (2014) (37)
- Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma. (2011) (36)
- Phase I/II Study of Hepatic Arterial Infusion Chemotherapy With Gemcitabine in Patients With Unresectable Intrahepatic Cholangiocarcinoma (JIVROSG-0301) (2011) (36)
- Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. (2009) (36)
- Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications (2008) (35)
- Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1). (2006) (35)
- Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer (2017) (34)
- A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors (2021) (34)
- Phase I trial of GBS‐01 for advanced pancreatic cancer refractory to gemcitabine (2016) (33)
- Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine (2017) (33)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial (2017) (33)
- Spontaneous regression of hepatocellular carcinoma with multiple lung metastases: a case report. (2001) (32)
- Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. (1998) (31)
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT). (2019) (30)
- Intratumor ethanol injection therapy for solitary minute hepatocellular carcinoma. A study of 37 patients. (1994) (28)
- A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma (2018) (28)
- Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. (2016) (27)
- Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. (2014) (27)
- Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment? (2009) (27)
- Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately (2019) (27)
- Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. (2002) (27)
- New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer (2019) (27)
- Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients (2018) (27)
- Transarterial Chemotherapy with Zinostatin Stimalamer for Hepatocellular Carcinoma (1998) (27)
- A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer (2007) (27)
- Transcatheter arterial infusion chemotherapy with cisplatin–lipiodol suspension in patients with hepatocellular carcinoma (2009) (27)
- Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer (2012) (26)
- Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort (2020) (26)
- Optimal management of patients with hepatocellular carcinoma treated with lenvatinib (2018) (26)
- Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. (2006) (26)
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. (2006) (26)
- His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk. (2008) (26)
- Liver cryptococcosis manifesting as obstructive jaundice in a young immunocompetent man: Report of a case (2008) (25)
- Hepatocellular carcinoma not detected with plain US: treatment with percutaneous ethanol injection under guidance with enhanced US. (1992) (25)
- Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 (2020) (25)
- Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib (2014) (25)
- Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors (2021) (25)
- Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. (2011) (25)
- Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. (2018) (24)
- Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases (2010) (24)
- Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy (2018) (24)
- Reactivation of hepatitis B virus in patients receiving chemotherapy. (2013) (24)
- Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). (2018) (23)
- Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors (2015) (23)
- Current status of hepatocellular carcinoma in Japan. (2013) (23)
- Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). (2020) (23)
- Cytotoxic chemotherapy for pancreatic neuroendocrine tumors (2015) (22)
- Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study (2021) (22)
- Clinical outcomes of gemcitabine plus nab-paclitaxel (GnP) in initially diagnosed locally advanced pancreatic cancer. (2018) (22)
- Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer (2020) (22)
- Prognosis of advanced pancreatic cancer patients with reference to calorie intake. (1998) (22)
- Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. (2006) (21)
- Phase II Study of Uracil-Tegafur in Patients with Metastatic Pancreatic Cancer (2002) (21)
- JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis (2021) (21)
- Transcatheter Arterial Embolization with Zinostatin Stimalamer for Hepatocellular Carcinoma (2002) (21)
- TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC). (2021) (21)
- Spontaneous regression of hepatocellular carcinoma (2006) (21)
- Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK‐333 (2011) (20)
- Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version) (2019) (20)
- A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer (2010) (20)
- Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) (2020) (19)
- Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer (2018) (19)
- Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. (2003) (19)
- A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma (2020) (19)
- Characteristic Pattern of Reactivation of Hepatitis B Virus during Chemotherapy for Solid Cancers (2012) (18)
- Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. (2018) (18)
- A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial) (2020) (18)
- Abstract CT061: A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results (2019) (18)
- Undifferentiated carcinoma of the liver with neuroendocrine features: a case report. (1998) (17)
- A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. (2020) (17)
- Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma (2015) (17)
- Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). (2008) (17)
- Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). (2018) (17)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. (2018) (17)
- Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate. (2012) (17)
- Chemoradiotherapy for Locally Advanced Pancreatic Carcinoma in Elderly Patients (2005) (17)
- Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients (2018) (16)
- LBA30Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) (2017) (16)
- Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms. (2017) (16)
- Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection (2002) (16)
- nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients (2020) (16)
- Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. (2020) (16)
- Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy (2018) (15)
- Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426). (2014) (15)
- Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (2019) (15)
- Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study (2021) (15)
- A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. (2005) (14)
- Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma. (2008) (14)
- TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). (2019) (14)
- Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition (2019) (14)
- Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC (2020) (14)
- Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). (2012) (14)
- [Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents]. (2010) (14)
- IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor). (2021) (14)
- Hepatic Arterial Infusion Chemotherapy with Epirubicin in Patients with Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis (2007) (14)
- Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C (2006) (13)
- Prognostic Factors in Patients with Hepatocellular Carcinoma Refractory or Intolerant to Sorafenib (2014) (13)
- Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma (2002) (13)
- Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents (2015) (12)
- A phase I study of the human anti‐activin receptor‐like kinase 1 antibody PF‐03446962 in Asian patients with advanced solid tumors (2016) (12)
- A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma (2017) (12)
- Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan (2016) (12)
- Final result of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma (2008) (12)
- Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy. (2014) (12)
- A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. (2019) (11)
- Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer (2018) (11)
- Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy (2022) (11)
- Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. (2007) (11)
- Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial (2014) (11)
- A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. (2000) (11)
- Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results. (2013) (11)
- The “histological replacement growth pattern” represents aggressive invasive behavior in liver metastasis from pancreatic cancer (2020) (11)
- Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma. (2021) (10)
- A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class (2018) (10)
- A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE). (2015) (10)
- Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05) (2017) (10)
- Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. (2020) (10)
- Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study. (2014) (10)
- Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. (2020) (10)
- Transarterial (Chemo)Embolization for Liver Metastases in Patients with Neuroendocrine Tumors (2017) (10)
- Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer (2018) (10)
- Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). (2015) (10)
- Emerging drugs for biliary cancer (2014) (10)
- Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites. (2010) (9)
- FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. (2007) (9)
- A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study. (2020) (9)
- Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer. (2005) (9)
- Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC). (2020) (9)
- Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2) (2020) (8)
- Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. (2003) (8)
- Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer (2021) (8)
- Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients (2012) (8)
- Current Status of Hepatocellular Carcinoma Treatment in Japan (2012) (8)
- Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). (2021) (8)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. (2018) (8)
- A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo (2017) (8)
- Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis. (2022) (8)
- The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. (2019) (8)
- Clinical outcome of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer. (2017) (8)
- Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System (2022) (8)
- Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study (2020) (8)
- AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype (2019) (8)
- Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study (2015) (8)
- Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC). (2015) (8)
- Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial (2023) (7)
- Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma (2022) (7)
- Neural Invasion Spreads Macrophage-Related Allodynia via Neural Root in Pancreatic Cancer (2018) (7)
- Phase I study of TAC‐101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma (2012) (7)
- A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors. (2021) (7)
- Mo1296 RELIMINARY RESULT OF COMPUTER AIDED DIAGNOSIS (CAD) PERFORMANCE USING DEEP LEARNING IN EUS-FNA CYTOLOGY OF PANCREATIC CANCER (2018) (7)
- Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma (2014) (7)
- Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy. (2017) (7)
- Gemcitabine in Patients With Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas (2013) (7)
- Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. (2015) (7)
- Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. (2022) (7)
- Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics (2013) (7)
- Germline mutations in cancer-predisposition genes in patients with biliary tract cancer (2019) (7)
- Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis (2021) (6)
- Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma (2012) (6)
- Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study) (2020) (6)
- Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma (2020) (6)
- Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α‐fetoprotein: Outcomes by treatment‐emergent ascites (2021) (6)
- Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. (2012) (6)
- A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors (2019) (6)
- Successful obliteration of bleeding duodenal varices by EUS-guided injection of N-butyl-2-cyanoacrylate (2017) (6)
- Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma (2014) (6)
- Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial. (2020) (6)
- Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer (2004) (6)
- Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study. (2020) (6)
- Phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. (2016) (6)
- Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives (2021) (5)
- A Phase I study of MEDI-575, a PDGFRα monoclonal antibody, in Japanese patients with advanced solid tumors (2015) (5)
- 217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma (2014) (5)
- Final results of JASPAC05: Phase II trial of neoadjuvant S-1 and concurrent radiotherapy followed by surgery in borderline resectable pancreatic cancer. (2019) (5)
- Integrated communication support program for oncologists, caregivers and patients with rapidly progressing advanced cancer to promote patient-centered communication: J-SUPPORT 1904 study protocol for a randomised controlled trial (2020) (5)
- Efficacy of S-1 compared to modified FOLFIRINOX as second-line chemotherapy regimens after gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic cancer. (2017) (5)
- Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer (2017) (5)
- A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization (2008) (5)
- Interim analysis of a phase 2 study of lenvatinib (LEN) monotherapy as second-line treatment in unresectable biliary tract cancer (BTC). (2017) (5)
- Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study (2020) (5)
- Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL) (2019) (5)
- Evaluation of Improvement of Adherence Following Pharmacist Intervention for Hand/Foot Skin Reactions Induced by Sorafenib (2011) (5)
- Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. (2018) (5)
- Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer (2018) (5)
- Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. (2020) (4)
- Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version) (2022) (4)
- Symptom changes that predict disease control by systemic chemotherapy in patients with advanced pancreatic cancer. (2012) (4)
- Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2019) (4)
- Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma (2019) (4)
- Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer (2019) (4)
- EUS-guided n-butyl-2-cyanoacrylate injection therapy for ruptured isolated left gastric artery pseudoaneurysm (2018) (4)
- Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study (2021) (4)
- IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. (2018) (4)
- Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report (2013) (4)
- Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC). (2020) (4)
- Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp) (2021) (4)
- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines) (2023) (4)
- TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs). (2018) (4)
- Prognosis of hepatocellular carcinoma with no tumor stain treated by percutaneous ethanol injection. (2001) (4)
- Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an AntiâÂÂInterleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer (2017) (4)
- A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer. (2019) (4)
- Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment (2016) (4)
- Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study (2019) (4)
- Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302 (2022) (4)
- Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial. (2015) (3)
- Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study. (2019) (3)
- Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC). (2008) (3)
- Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer (2020) (3)
- Response Evaluation Criteria in Cancer of the Liver version 6 (RECICL 2021 Revised Version). (2022) (3)
- Phase I study of safety, pharmacokinetics, and efficacy of TSU-68 plus S-1 combination in patients with advanced hepatocellular carcinoma. (2013) (3)
- Clinical impact of radiofrequency ablation and stereotactic body radiation therapy for colorectal liver metastasis as local therapies for elderly, vulnerable patients (2020) (3)
- Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer (2020) (3)
- Expansion part of phase I study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression. (2020) (3)
- A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC). (2013) (3)
- The effect of duloxetine on chemotherapy-induced peripheral neuropathy in advanced pancreatic cancer patients receiving gemcitabine plus nab-paclitaxel treatment. (2017) (3)
- A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer (2021) (3)
- FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study (2021) (3)
- Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer: Pegasus-PC study. (2013) (3)
- Predictive factors for tumor response to chemotherapy in patients with pancreatic cancer. (2000) (3)
- SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. (2018) (3)
- Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer (2022) (3)
- Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). (2018) (3)
- Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer (2019) (2)
- [Non-surgical treatment for pancreatic cancer]. (2006) (2)
- 1236 POSTER Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of the Multikinase Inhibitor Regorafenib (BAY 73-4506) in Japanese Patients With Advanced Solid Tumours (2011) (2)
- Clinicopathological features in misdiagnosed pancreatic carcinoma. (1999) (2)
- Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG1106). (2015) (2)
- Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (2019) (2)
- A randomized phase III trial comparing adjuvant chemotherapy with S-1 vs. surgery alone in patients with resectable biliary tract cancer (JCOG1202: ASCOT). (2017) (2)
- A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1. (2023) (2)
- Results from phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer. (2019) (2)
- Comparison of morphological features in lymph node metastasis between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinomas. (2020) (2)
- Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC) (2021) (2)
- Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) (2020) (2)
- Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis (2019) (2)
- Chemotherapy for advanced hepatocellular carcinoma, Japanese perspective. (2018) (2)
- [Immune checkpoint inhibitors in hepatocellular carcinoma]. (2019) (2)
- Risk Factor of the Hand/foot Skin Reaction Induced by Sorafenib in Patients with Advanced Hepatocellular Carcinoma (2013) (2)
- REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study. (2021) (2)
- Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? (2015) (2)
- Prophylactic Use of Urea-based Cream for Hand-foot Skin Reaction Associated with Sorafenib (2015) (2)
- IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma—An Exploratory Analysis of the Phase III Study (2022) (2)
- TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial). (2017) (2)
- Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer (2022) (2)
- Endoscopic unroofing drainage with a needle-knife for gastric wall abscess: a rare adverse event that developed after EUS-FNA (2019) (1)
- Abstract CT213: Arctigenin, an antiausterity agent shows high safety and promising clinical response in phase I clinical trial in patient with gemcitabine-refractory pancreatic cancer (2014) (1)
- Endoscopic Ultrasound-Guided Gallbladder Drainage for Aberrant Right Posterior Duct Obstruction Developing after Placement of a Covered Self-Expandable Metallic Stent in a Patient with Distal Biliary Obstruction (2018) (1)
- Phase II trial of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer: Interim results of JASPAC05. (2017) (1)
- 6587 POSTER A Phase 1b, Open-Label Study to Evaluate the Safety of Ganitumab (AMG 479) in Combination With Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer (2011) (1)
- Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. (2022) (1)
- Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD). (2013) (1)
- Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). (2018) (1)
- Risk stratification and prognostic factors in patients with unresectable undifferentiated carcinoma of the pancreas. (2021) (1)
- A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma (HCC). (2014) (1)
- O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study (2020) (1)
- Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study (2020) (1)
- Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials (2022) (1)
- [Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]. (2006) (1)
- A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy. (2018) (1)
- O1–039CHARACTERIZATION OF PATIENT WITH HIGH SERUM LEVEL OF IL-6 IN ADVANCED PANCREATIC CANCER (2013) (1)
- 6610 Hepatocellular carcinoma presenting with lung metastasis: clinical characteristics and prognostic factors (2009) (1)
- A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma (2020) (1)
- [Chemotherapy for hepatocellular carcinoma]. (2004) (1)
- Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC). (2021) (1)
- Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours (2019) (1)
- 68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis (2021) (1)
- Techniques to Prepare Epirubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma:Additional Survey of the Japanese Institutions in a Cooperative Study between Korea and Japan (2013) (1)
- Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC) (2016) (1)
- Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial (2014) (1)
- Phase 1 studies of 3- and 6-peptide vaccine cocktail derived from GPC3, WDRPUH, and NEIL3 in patients with advanced hepatocellular carcinoma (HCC). (2018) (1)
- Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer (2021) (1)
- Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis. (2022) (1)
- A phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. (2013) (1)
- 196 The efficacy, toxicity and pharmacokinetic findings of S-1 in patients (pts) with advanced biliary tract cancer (BTC): a phase II trial (2003) (1)
- A case of pancreatic cancer achieving symptomatic improvement with systemic chemotherapy. (1999) (1)
- Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study (2023) (1)
- Phase I/II Trial of Lenvatinib (E7080), A Multi-Targeted Tyrosine Kinase Inhibitor, in Patients (PTS) with advanced Hepatocellular Carcinoma (HCC) (2012) (1)
- Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC). (2015) (1)
- Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment (2013) (1)
- Evaluation of the ideal pancreatic cancer classroom: Report on the status of activities at nine major institutions (2020) (1)
- Ramucirumab in patients with advanced hepatocellular carcinoma and elevated <i>α</i>╒fetoprotein: Outcomes by treatment╒emergent ascites (2021) (1)
- A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. (2011) (1)
- Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites. (2020) (1)
- Multicenter observational study of reactivation of hepatitis B virus (HBV) caused by chemotherapy for solid tumors (ST). (2014) (1)
- Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study). (2020) (1)
- The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 (2022) (1)
- Response Evaluation Criteria in Cancer of the Liver (RECICL 2019 revised version) (2019) (1)
- A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy (2021) (1)
- Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study. (2023) (1)
- S100P tumor-marker response to chemotherapy in patients with advanced pancreatic cancer. (2015) (1)
- Su1199 WHICH STENT IS OPTIMIZING,PLASTIC OR METAL FOR EUS-HGS AFTER FAILED ERCP? (2019) (1)
- Primary Hepatocellular Carcinoma Detected Long After Tumor Markers and Lymph Node Metastases—Beyond Our Vision? (2006) (1)
- P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (2021) (1)
- 3553 POSTER Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part – Correlation between pharmacokinetics (PK) and hepatic dysfunction (2007) (0)
- Contents Vol. 92, 2017 (2017) (0)
- Abstract 2238: RAS activity-related features of metastatic pancreatic cancer (2023) (0)
- O3-10-5LOSS OF STAT3 TYROSINE PHOSPHORYLATION IN TUMOR RELATES POOR PROGNOSIS IN PATIENTS WITH ADVANCED PANCREATIC CANCER (2014) (0)
- Lenvatinib as an Initial Treatment in Patients with Intermediate-stage Hepatocellular Carcinoma Beyond up-to-seven Criteria and Child-Pugh A Liver Function: A Proof-of-Concept Study (2019) (0)
- Phase I and pharmacokinetic study of 5-fluorouracil (5-FU) 5-day continuous infusion in hepatocellular carcinoma (HCC) patients with liver cirrhosis (LC) (1998) (0)
- Cholangioscopic diagnosis of hemobilia: an unusual case of left hepatic portal hypertension by plasma cell tumor (2022) (0)
- SY11-6ADJUVANT S-1 THERAPY FOR PATIENTS WITH RESECTED BILIARY TRACT CANCER (2014) (0)
- [Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent]. (2014) (0)
- The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113. (2022) (0)
- Clinical and molecular features of responders to PD-1 blockade for patients with microsatellite instability high or mismatch repair deficient advanced gastrointestinal tumors. (2020) (0)
- Contents Vol. 58, 2000 (2000) (0)
- Tu1406 COMPREHENSIVE ANALYSIS FOR ADVERSE EVENTS BY ENDOSCOPIC ULTRASOUND-GUIDED HEPATICOGASTROSTOMY (EUS-HGS) IN MALIGNANT BILIARY OBSTRUCTION (2019) (0)
- 1034 DOES EUS GUIDED HEPATICOGASTROSTOMY AFFECT CHOLANGITIS IN INCIDENCE AND BACTERIA ETIOLOGY? (2020) (0)
- Su1239 SAFETY AND FEASIBILITY OF CONVERSION FROM PERCUTANEOUS TRANSHEPATIC GALLBLADDER DRAINAGE TO TRANSMURAL ENDOSCOPIC ULTRASOUND-GUIDED GALLBLADDER DRAINAGE FOR ACUTE CHOLECYSTITIS IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION (2019) (0)
- Electronic patient-reported outcome measured in patients with pancreatic cancer receiving second-line chemotherapy: A multicenter prospective observational study. (2023) (0)
- Clinicopathological features and response to platinum-based chemotherapy in pancreatic neuroendocrine carcinoma: A retrospective multicenter study of 70 patients. (2016) (0)
- Measurement of urinary kininogen (KNG) fragments as a noninvasive tool for early diagnosis of pancreatic cancer (PaCa). (2019) (0)
- Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (2019) (0)
- Pancreas resection for unresectable locally advanced pancreatic cancer (LAPC): Resection rate in the era of FOLFIRINOX and GEM+nabPTX. (2016) (0)
- Mo1346 THERAPEUTIC EFFECTS OF ENDOSCOPIC ULTRASOUND-GUIDED CELIAC NEUROLYSIS (EUS-CPN) IN PATIENTS WITH UPPER ABDOMINAL-ASSOCIATED PAIN (UAP) (2018) (0)
- [Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy]. (2007) (0)
- Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study (2020) (0)
- SY10-5 Future perspectives of systemic therapy for hepatocellular carcinoma (2022) (0)
- Contents Vol. 59, 2000 (2000) (0)
- Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites (2010) (0)
- Front & Back Matter (2019) (0)
- Su1275 FACTORS ASSOCIATED WITH RECURRENT CHOLECYSTITIS AFTER EUS-GBD FOR ACUTE CHOLECYSTITIS IN PATIENTS WITH UNRESECTABLE MALIGNANCIES (2020) (0)
- Impact of glycemic control on treatment efficacy and safety during nabpaclitaxel plus gemcitabine therapy in unresectable pancreatic cancer. (2019) (0)
- The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113. (2019) (0)
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular (2015) (0)
- Revisions of the clinical practice guidelines for hepatocellular carcinoma in 2021 version (2023) (0)
- O2-8-1Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial (2015) (0)
- MO23-6 A single-center experience of comprehensive genomic profiling of hepatobiliary and pancreatic cancers (2022) (0)
- Nivolumab for treating patients with occupational cholangiocarcinoma (2022) (0)
- Front & Back Matter (2019) (0)
- Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603). (2018) (0)
- Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study. (2023) (0)
- Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT). (2023) (0)
- [Systemic therapy for hepatocellular carcinoma: from molecular targeted agent to combined immunotherapy]. (2023) (0)
- Abstract CT565: Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer (2022) (0)
- Subject Index Vol. 59, 2000 (2000) (0)
- O1-17-3Safety and efficacy of modified FOLFIRINOX in patients with metastatic pancreatic cancer (2015) (0)
- Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer (2019) (0)
- PhaseIStudyofFixedDoseRateInfusionofGemcitabineinPatients with Unresectable Pancreatic Cancer (2005) (0)
- Safety, PK and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors; Phase 1 Study (2019) (0)
- IS2-4CURRENT STATUS AND PERSPECTIVE OF CHEMOTHERAPY FOR UNRESECTABLE PANCREATIC NEUROENDOCRINE CARCINOMA (2014) (0)
- [Chemotherapy for gallbladder cancer]. (2013) (0)
- Short communication Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma (2003) (0)
- S100A8/A9 as a potent serological marker in monitoring the activity of chemotherapy in pancreatic cancer. (2015) (0)
- Front & Back Matter (2019) (0)
- Contents Vol. 68, 2005 (2005) (0)
- Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 (2017) (0)
- Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial (2022) (0)
- Contents Vol. 8, 2019 (2019) (0)
- O2-9-2Modified FOLFIRINOX in pancreatic cancer patients with double variant type of UGT1A1 polymorphism (2015) (0)
- Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer treated with gemcitabine and nab-paclitaxel. (2019) (0)
- SY-2-1Evidence of reactivation of hepatitis B virus in patients receiving chemotherapy for malignancies (2016) (0)
- 6623 Cisplatin plus etoposide as first-line chemotherapy for poorly- differentiated neuroendocrine carcinoma of the hepatobiliary and pancreatic region (2009) (0)
- 43 POSTER Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC) (2008) (0)
- Phase II trial of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer (JASPAC05). (2018) (0)
- Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC). (2021) (0)
- O2-13-4EFFICACY AND POSSIBLE BIOMARKER OF GEMCITABINE AND ERLOTINIB FOR ADVANCED PANCREATIC CANCER (2014) (0)
- Predictive factors of outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. (2018) (0)
- Successful endoscopic closure of an esophageal leak after endoscopic ultrasound-guided hepaticoesophagostomy by using n-butyl-2 cyanoacrylate (2019) (0)
- Su1194 DEVELOPMENT OF PRTOTYPE EUS GUIDED FORCEPS NEEDLE BIOPSY (EUS-FNB) (2019) (0)
- Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. (2019) (0)
- Clinicopathological features and response to platinum-based chemotherapy (PBC) in pancreatic neuroendocrine carcinoma (pNEC): Updated results of Japan pNEC study. (2016) (0)
- Front & Back Matter (2019) (0)
- Depth of response in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory subgroup analysis of JCOG1407. (2023) (0)
- IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study. (2023) (0)
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies (2020) (0)
- Serum microRNAs as tumor markers for diagnosis of pancreatic cancer (2017) (0)
- Mo1099 ENDOSCOPIC MANAGEMENT AND STRATEGY OF A LARGE IATROGENIC DUODENAL FREE-WALL PERFORATION DURING EUS AND ERCP RELATED PROCEDURE (2019) (0)
- Indication for local ablation therapy for small HCC with reference to intrahepatic metastasis (2001) (0)
- Safety, Pharmacokinetics, and Preliminary Efficacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 Study (2021) (0)
- [5 -fluoropyrimidines for treatment of biliary tract cancers]. (2006) (0)
- Front & Back Matter (2018) (0)
- [Palliative therapy in patients with biliary tract cancer]. (2006) (0)
- Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma (2022) (0)
- Circulating calprotectin, innate inflammatory protein, was decreased under disease control during first-line chemotherapy for advanced pancreatic cancer. (2019) (0)
- 2312 Japanese phase I trial of hypoxia-activated prodrug evofosfamide (TH-302) as monotherapy in patients with solid tumors or in combination with gemcitabine in patients with advanced pancreatic cancer (2015) (0)
- Front & Back Matter (2019) (0)
- P17-5 Early onset of anorexia-cachexia related worsening of cachexia symptoms during chemotherapy for pancreatic cancer (2022) (0)
- Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 (2021) (0)
- Front & Back Matter (2019) (0)
- Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552]. (2019) (0)
- Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). (2017) (0)
- Analysis of early tumor shrinkage and depth of response in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin or gemcitabine plus S-1: An exploratory analysis of JCOG1113. (2021) (0)
- Comparison of clinical features by primary sites in patients with biliary tract cancer who received gemcitabine-based chemotherapy: An exploratory analysis of JCOG1113. (2023) (0)
- Early detection of pancreatic ductal adenocarcinoma using abnormal urinary fragmentation ratio of a liver-originated protein. (2019) (0)
- Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma (2022) (0)
- Risk factors of chemotherapy-induced nausea and vomiting in patients with advanced pancreatic cancer receiving modified FOLFIRINOX. (2016) (0)
- FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 polymorphism: A multicenter, retrospective study. (2018) (0)
- Pancreatic neuroendocrine tumors: Twenty years' experience of 100 patients at a single center. (2012) (0)
- SY2-7NEW AGENTS UNDER DEVELOPMENT FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN JAPAN (2014) (0)
- Effects of gene expression in 5-FU metabolic pathways in a phase III trial evaluating adjuvant S-1 therapy compared to surgery alone following curative resection for biliary tract cancer (JCOG1202A1). (2023) (0)
- [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. (2015) (0)
- An investigator-initiated phase II trial of a PARP inhibitor niraparib monotherapy for patients with pre-treated, BRCA-mutated, unresectable/recurrent biliary tract, pancreatic, and other gastrointestinal cancers (NIR-B trial). (2022) (0)
- Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors (2023) (0)
- Rb expression and KRAS mutation as predictors of response to platinum-based chemotherapy (PBC) of small and large cell neuroendocrine carcinoma (NEC): A subgroup analysis of the Japan pNEC study (2016) (0)
- Abstract CT177: A phase I, first in human study of CBA-1205, glycoengineered humanized anti-DLK-1 monoclonal antibody in patients with advanced solid tumors (2023) (0)
- Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab (2022) (0)
- Association of gemcitabine (GEM) efficacy on unresectable invasive pancreatic carcinoma with intraductal papillary mucinous neoplasms. (2015) (0)
- A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice. (2023) (0)
- Thanking All Peer Reviewers. (2015) (0)
- Hepatic angiomyolipoma mimicking hepatocellular carcinoma (2009) (0)
- Contents Vol. 7, 2018 (2018) (0)
- Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma. (2022) (0)
- Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN. (2023) (0)
- The time trends of gallbladder cancer and cholangiocarcinoma in 1,047 patients. (2014) (0)
- Risk factors for early relapse in patients with biliary tract cancers who underwent curative resection: An exploratory subgroup analysis of JCOG1202. (2023) (0)
- 6595 POSTER Phase I Study of Gemcitabine as a Fixed Dose Rate Infusion and S-1 Combination Therapy (FGS) in Gemcitabine-refractory Biliary Tract Cancer (BTC) Patients (2011) (0)
- Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study. (2023) (0)
- Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study (2018) (0)
- DEVELOPMENT OF STRATEGIES FOR NON-SURGICAL TREATMENT IN PANCREATIC CANCER (2007) (0)
- Tu1575 Endoscopic Side-By-Side Bilateral Biliary Drainage Using Longer Model Uncovered SEMS for Hilar Malignant Obstruction -a Single Institution Experience (2016) (0)
- Front & Back Matter (2020) (0)
- Protocol of a randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer: JCOG1611 (GENERATE) (2022) (0)
- Management of Local and Distant Recurrence after Pancreatic Cancer Resection (2015) (0)
- Front & Back Matter (2018) (0)
- The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113. (2019) (0)
- Impact of Proton Beam Irradiation of an Anatomical Subsegment of the Liver for Hepatocellular Carcinoma. (2020) (0)
- Transarterial infusion chemotherapy with cisplatin plus S-1 for treating hepatocellular carcinoma: Results of a phase I trial. (2012) (0)
- O2-13-3A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL(nab-P)+ GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC) (2014) (0)
- Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/β-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors (2022) (0)
- Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study. (2021) (0)
- Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC). (2023) (0)
- Benefits of measuring urinary protein/creatinine ratio in lenvatinib treatment for unresectable hepatocellular carcinoma. (2023) (0)
- Abstract 6686: Tumor suppressor miRNA-665 based serum biomarker for detecting pancreatobiliary cancer (2023) (0)
- [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma]. (2012) (0)
- PD4-2Reactivation of hepatitis B viral infection in patients with solid tumor receiving chemotherapy (2015) (0)
- Mo1275 EUS-GUIDED HEPATOGASTROSTOMY IS THE LAST RESORT BILIARY DRAINAGE IN MALIGNANT BILIARY OBSTRUCTION AFTER FAILED ERCP (2018) (0)
- Influence of obstructive jaundice on chemotherapy in patients with unresectable biliary tract cancer. (2014) (0)
- O1-17-1Characterization of a loss of skeletal muscle mass in advanced pancreatic cancer patients receiving chemotherapy (2016) (0)
- Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in advanced pancreatic cancer patients. (2014) (0)
- Abstract B29: Feasibility of amplicon sequencing using a pan-cancer gene panel with pre-treatment biopsy samples of (Japanese) patients with advanced solid tumors: Analyses of Biopsy Samples for Cancer Genomics (ABC) study. (2013) (0)
- Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer. (2018) (0)
- Early detection of pancreatic ductal adenocarcinoma by measuring the abnormal urinary fragmentation ratios of kininogen (2019) (0)
- P1-8-8FOLFIRINOX for locally advanced or metastatic pancreatic cancer: a single institution retrospective review (2015) (0)
- The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 (2022) (0)
- Comparison of the frequency of adverse events requiring interventions determined by telephone follow up in hepatocellular carcinoma patients treated with sorafenib and lenvatinib. (2020) (0)
- 4. Molecularly Targeted Agent (2014) (0)
- Subject Index Vol. 58, 2000 (2000) (0)
- Perspectives in Therapy for Pancreatic Neuroendocrine Carcinomas (2009) (0)
- A multicenter phase II study of sorafenib in Japanese patients with hepatocellular carcinoma and Child Pugh A or B cirrhosis. (2014) (0)
- Effect of inflammatory and nutritional (IN) status on induction chemotherapy (CT) followed by chemoradiotherapy (CRT) for locally advanced pancreatic cancer (LAPC): An exploratory subgroup analysis of JCOG1106. (2017) (0)
- MicroRNA markers for the detection of resectable pancreatic cancer (2016) (0)
- MO38-3 Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090 (2021) (0)
- The identification of the age effects in 1,287 patients with biliary tract cancer. (2015) (0)
- Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. (2020) (0)
- Front & Back Matter (2018) (0)
- Su1264 EUS-GUIDED HEPATICOGASTROSTOMY AS SALVAGE TREATMENT FOR ACUTE CHOLANGITIS SECONDARY TO HILAR MALIGNANT OBSTRUCTION (2020) (0)
- Abstract 6145: Increased PD-L1 expression levels were observed on both tumor cells and macrophages by tocilizumab plus gemcitabine/nab-paclitaxel treatment in gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer patients (2022) (0)
- Systemic therapy for hepatocellular carcinoma: current status and future perspectives. (2021) (0)
- Su1901 Severe Neural Invasion Related to Cachexia in Advanced Pancreatic Cancer (2014) (0)
- Conversion of percutaneous cholecystostomy to transmural endoscopic ultrasound-guided gallbladder drainage in malignant biliary obstruction (2019) (0)
- Clinical features of hemobilia in unresectable pancreatic cancer (uPC). (2018) (0)
- Chemotherapy for hepatocellular carcinoma: molecular targeted agents, hepatic arterial infusion chemotherapy or both? (2017) (0)
- Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. (2022) (0)
- Characterization of patients with high serum level of IL-6 in advanced pancreatic cancer. (2014) (0)
- Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer: Additional safety report of randomized Japanese phase 2 trial. (2022) (0)
- MO2-3 Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer – Additional safety report of randomized Japanese phase 2 trial (2022) (0)
- AB046. P-14. TREETOPP: a phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs) (2019) (0)
- Front & Back Matter (2020) (0)
- O1-17-4Updated analysis of weekly nab-Paclitaxel (P)+ Gemcitabine (G) with metastatic pancreatic cancer (MPC): Phase I / II trial (2015) (0)
- Frequency of severe neutropenia occurring as an adverse events of gemcitabine plus cisplatin chemotherapy in patients with recurrent biliary tract cancer compared to those with unresectable biliary tract cancer. (2017) (0)
- Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study. (2023) (0)
- ISY-21-2Current status of FOLFIRINOX in Japan: modified or original? (2016) (0)
- ISY-12-1Current status of biotherapies and chemotherapies for GEP-NETs (2016) (0)
- Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification (2018) (0)
- Phase I Study of FixedDoseRate Infusion ofGemcitabine in Patients with Unresectable Pancreatic Cancer (2005) (0)
- Su1262 A FEASIBILITY AND SAFETY OF EUS-GUIDED HEPATICOESOPHAGOSTOMY AS A TRANSESOPHAGEAL EUS-BD (2020) (0)
- A phase II trial of continuous-infusion 5-fluorouracil, mitoxantone and cisplatin for metastatic hepatocellular carcinoma. (2004) (0)
- Sa1412 SAFETY AND FEASIBILITY OF A BRAND-NEW ELECTROCAUTERY DILATOR BY HBRID-MECHANICAL AND CAUTERIZED USE FOR EUS-GUIDED HEPATICOGASTROSTOMY (2020) (0)
- 590 – High Diagnostic Yield Using Advanced Artificial Intelligence in Cytology of Pancreatic Cancer by Eus-Fna (2019) (0)
- [S-1 monotherapy for pancreatic cancer]. (2006) (0)
- Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study) Clinical Trial Results (2021) (0)
- Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer (2023) (0)
- A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). (2022) (0)
- Front & Back Matter (2018) (0)
- Multidisciplinary fatigue management in patients treated with lenvatinib (2021) (0)
- Subject Index Vol. 68, 2005 (2005) (0)
- Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer (2019) (0)
- WS6-2LIVER DYSFUNCTION: CHEMOTHERAPY IN PATIENTS WITH CURRENT OR RESOLVED HEPATITIS B VIRAL INFECTION (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Masafumi Ikeda?
Masafumi Ikeda is affiliated with the following schools:
